gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.
about
The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugsThe GenoType® MTBDR sl test for resistance to second-line anti-tuberculosis drugsThe Race Is On To Shorten the Turnaround Time for Diagnosis of Multidrug-Resistant TuberculosisGenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugsThe rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaksProgrammatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South AfricaWhole genome sequencing based characterization of extensively drug-resistant Mycobacterium tuberculosis isolates from PakistanDiagnostic Molecular Mycobacteriology in Regions With Low Tuberculosis Endemicity: Combining Real-time PCR Assays for Detection of Multiple Mycobacterial Pathogens With Line Probe Assays for Identification of Resistance MutationsComparison of TaqMan(®) Array Card and MYCOTB(TM) with conventional phenotypic susceptibility testing in MDR-TB.New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in MycobacteriaMoxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis.Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countriesMolecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis.Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assayPharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment.Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomesPrimary Capreomycin Resistance Is Common and Associated With Early Mortality in Patients With Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosisAssessment of a 96-Well Plate Assay of Quantitative Drug Susceptibility Testing for Mycobacterium Tuberculosis Complex in China.QSAR based therapeutic management of M. tuberculosis.Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosisMutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates.Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosisMoxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant TuberculosisImpact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use.Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis.Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.Moxifloxacin retains antimycobacterial activity in the presence of gyrA mutations.Medical treatment of pulmonary multidrug-resistant tuberculosis.Exploration of fluoroquinolone resistance in Streptococcus pyogenes: comparative structure analysis of wild-type and mutant DNA gyrase.Increased Tuberculosis Patient Mortality Associated with Mycobacterium tuberculosis Mutations Conferring Resistance to Second-Line Antituberculous Drugs.Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis.In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests.A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.
P2860
Q24193002-CDE3B0F4-110F-4778-8044-6C3656069958Q24200646-44D83BE8-054D-40E2-AB5A-90269D6A1880Q26785997-7B5F4F11-C62D-492A-A74C-9C85B3C5D538Q28068545-B9B1B9FB-4688-4D04-9B44-463D92615B0AQ28488204-AA32A3B6-F83F-4CED-B12A-E1C30FE2E861Q28535594-6A84D4EE-E3D3-4C35-965F-34965E8E4E83Q28543682-59B12905-4697-4C82-8122-F30CEDBA9073Q28831411-912D8FAB-ABC2-4399-B80E-8CEC082C764DQ30276393-1FAF408A-CBE3-440E-8935-9ABE78E353CFQ33600161-707B38BE-0F6B-48AC-89FD-9FB80621FB9FQ34109856-A18FC56E-DECD-4748-893B-3C132DC89267Q34922635-626046D2-A4EF-4F3B-BC8C-66589022D866Q35076978-3E2EA140-0F13-4456-B8B2-6EA0E7C26413Q35181330-96C06CC3-5AD1-4C71-8A88-3F170BAB3521Q35197257-81DBD75A-F7D0-4958-B31D-1B9F04ECC990Q35800272-A0319058-36CB-43CA-BED5-54DF396C813FQ35805940-567DD64F-2A26-4ED8-B4F4-A3C389E8DE07Q35850402-D3EEEAF6-FB20-4D5C-AAB8-2172B44BA576Q35960685-1EC214D1-3DE0-4613-A81C-7B41D617C22AQ36086373-81BA0348-B096-401A-B8B2-0937A833143CQ36247548-38A5AEA2-16D9-4E7A-B001-C17B3BFBDBF6Q36359056-889BEE0C-E228-4276-A15F-A9E4019AA944Q36620922-D1602DB8-C199-4803-BB8C-21BD2C842FB1Q36730001-92C2D16E-3230-4F12-8450-B57DA872F0F2Q37089655-75E2CA2E-EA5D-4374-A56F-CC3D8F0CBE1DQ37120071-654D7CB4-96F2-454C-9F5A-94F8EBD0A7F6Q37124036-639B3FC2-D3B9-4405-B929-1744840F2C2FQ37191156-A63E0144-6D78-42AE-97DB-D27C1812E9A3Q37544479-0BE3A57B-BCF7-477B-A97A-C6064A33BE5AQ37581864-F4D671BB-B178-4CF0-98C2-E6D6A788B858Q37682208-F0D51656-E6CA-45AA-8890-1779073FA2B3Q37712966-C577834E-3C20-4143-B586-DBFBA810BDE9Q37713049-9006367B-2316-46EF-8479-EC166460D6EAQ38182982-5330AFA9-B258-4BDB-B076-62B6BD375B8EQ38408892-3377BF34-9450-47D3-AACC-8893BD05A28CQ38839490-6871A653-CFF2-4EC0-901F-0C4198FB9038Q38845761-8376BACE-2F61-457E-8538-10BE0401CCE2Q38848119-7367DF2E-EE01-41BB-B9D2-C7F6E23C14C5Q39412049-0AFEAC48-CE21-49BF-B713-292E29ECC2E8Q39456569-580D9F67-4ED5-474C-B91C-BB9E29D4882A
P2860
gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
gyrA mutations and phenotypic ...... of Mycobacterium tuberculosis.
@en
gyrA mutations and phenotypic ...... of Mycobacterium tuberculosis.
@nl
type
label
gyrA mutations and phenotypic ...... of Mycobacterium tuberculosis.
@en
gyrA mutations and phenotypic ...... of Mycobacterium tuberculosis.
@nl
prefLabel
gyrA mutations and phenotypic ...... of Mycobacterium tuberculosis.
@en
gyrA mutations and phenotypic ...... of Mycobacterium tuberculosis.
@nl
P2093
P2860
P356
P1476
gyrA mutations and phenotypic ...... of Mycobacterium tuberculosis.
@en
P2093
Erik C Böttger
Frederick A Sirgel
Paul D van Helden
Thomas C Victor
P2860
P304
P356
10.1093/JAC/DKS033
P407
P577
2012-02-22T00:00:00Z